Michel M. van den Heuvel

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 628 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Comprehensive Health Assessment 3 Months After Recovery From Acute Coronavirus Disease 2019 (COVID-19)

Bram van den Borst, Jeannette B. Peters, Monique Brink et al. · Clinical Infectious Diseases · 2020 · 493 citations · Full text

Medicine, Infectious Diseases, Radiology +15

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score

Amelia Clive, Brennan C Kahan, Clare Hooper et al. · Thorax · 2014 · 440 citations · Full text

Public Health, Biostatistics, Oncology +15

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2017 · 419 citations · Full text

Medicine, Oncology, Pharmacology +17